John V. Sakys's most recent trade in Mesa Laboratories, Inc. was a trade of 1,036 Restricted Stock Units - 6 done . Disclosure was reported to the exchange on June 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2025 | 1,036 | 1,036 | - | - | Restricted Stock Units - 6 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.82 per share. | 21 Jun 2025 | 1,036 | 15,498 (0%) | 0% | 95.8 | 99,270 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 95.82 per share. | 21 Jun 2025 | 454 | 15,044 (0%) | 0% | 95.8 | 43,502 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,840 | 5,511 | - | - | Restricted Stock Units - 7 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 92.99 per share. | 18 Jun 2025 | 2,840 | 15,705 (0%) | 0% | 93.0 | 264,092 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.99 per share. | 18 Jun 2025 | 1,243 | 14,462 (0%) | 0% | 93.0 | 115,587 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2025 | 8,133 | 8,133 | - | - | Restricted Stock Units - 8 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2025 | 793 | 12,839 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2025 | 793 | 0 | - | - | Restricted Stock Units - 5 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2025 | 668 | 13,507 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 97.12 per share. | 15 Jun 2025 | 642 | 12,865 (0%) | 0% | 97.1 | 62,350 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 10 Jun 2025 | 4,087 | 19,706 | - | - | Non Qualified Stock Options | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,037 | 2,072 | - | - | Restricted Stock Units - 6 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,037 | 12,500 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 133.69 per share. | 01 Sep 2024 | 454 | 12,046 (0%) | 0% | 133.7 | 60,695 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 8,351 | 8,351 | - | - | Restricted Stock Units - 7 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,304 | 12,035 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 793 | 793 | - | - | Restricted Stock Units - 5 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.60 per share. | 14 Jun 2024 | 572 | 11,463 (0%) | 0% | 91.6 | 52,395 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 511 | 0 | - | - | Restricted Stock Units - 3 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 02 Apr 2024 | 2,500 | 23,793 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 5,619 | 26,293 | - | - | Non Qualified Stock Options | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 848 | 11,019 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 396 | 1,586 | - | - | Restricted Stock Units - 5 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 135.55 per share. | 16 Jun 2023 | 288 | 10,731 (0%) | 0% | 135.5 | 39,038 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 256 | 511 | - | - | Restricted Stock Units - 3 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 196 | 0 | - | - | Restricted Stock Units - 1 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 848 | 10,544 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 396 | 1,982 | - | - | Restricted Stock Units - 5 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 134.45 per share. | 15 Jun 2023 | 373 | 10,171 (0%) | 0% | 134.5 | 50,150 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 256 | 767 | - | - | Restricted Stock Units - 3 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 196 | 196 | - | - | Restricted Stock Units - 1 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 122.66 per share. | 22 Mar 2023 | 2,500 | 12,196 (0%) | 0% | 122.7 | 306,650 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 171.62 per share. | 22 Mar 2023 | 2,500 | 9,696 (0%) | 0% | 171.6 | 429,050 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 22 Mar 2023 | 2,500 | 23,802 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.85 per share. | 22 Mar 2023 | 1,128 | 10,824 (0%) | 0% | 51.9 | 58,487 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 22 Mar 2023 | 1,128 | 21,674 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 167.01 per share. | 22 Mar 2023 | 1,128 | 9,696 (0%) | 0% | 167.0 | 188,387 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 167.01 per share. | 22 Mar 2023 | 1,000 | 9,696 (0%) | 0% | 167.0 | 167,010 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 122.66 per share. | 22 Mar 2023 | 1,000 | 10,696 (0%) | 0% | 122.7 | 122,660 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 22 Mar 2023 | 1,000 | 22,802 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 15 Mar 2023 | 1,000 | 25,302 | - | - | Incentive Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 165.71 per share. | 15 Mar 2023 | 1,000 | 9,696 (0%) | 0% | 165.7 | 165,710 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.56 per share. | 15 Mar 2023 | 1,000 | 10,696 (0%) | 0% | 70.6 | 70,560 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.56 per share. | 09 Mar 2023 | 400 | 10,096 (0%) | 0% | 70.6 | 28,224 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 09 Mar 2023 | 400 | 26,302 | - | - | Incentive Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 169.97 per share. | 09 Mar 2023 | 400 | 9,696 (0%) | 0% | 170.0 | 67,988 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 184.27 per share. | 09 Feb 2023 | 1,000 | 9,696 (0%) | 0% | 184.3 | 184,270 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 09 Feb 2023 | 1,000 | 26,702 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.85 per share. | 09 Feb 2023 | 1,000 | 10,696 (0%) | 0% | 51.9 | 51,850 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 210.19 per share. | 23 Jan 2023 | 2,100 | 9,696 (0%) | 0% | 210.2 | 441,399 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 23 Jan 2023 | 2,100 | 27,702 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.56 per share. | 23 Jan 2023 | 2,100 | 11,796 (0%) | 0% | 70.6 | 148,176 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 1,303 | 9,981 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 1,303 | 0 | - | - | Restricted Stock Units - 4 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 178.42 per share. | 01 Sep 2022 | 799 | 9,696 (0%) | 0% | 178.4 | 142,558 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 514 | 10,495 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 514 | 1,023 | - | - | Restricted Stock Units - 3 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 15 Aug 2022 | 1,372 | 29,802 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.56 per share. | 15 Aug 2022 | 1,372 | 10,678 (0%) | 0% | 70.6 | 96,808 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 200.58 per share. | 15 Aug 2022 | 1,372 | 8,678 (0%) | 0% | 200.6 | 275,196 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.56 per share. | 15 Aug 2022 | 628 | 9,306 (0%) | 0% | 70.6 | 44,312 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 200.54 per share. | 15 Aug 2022 | 628 | 10,050 (0%) | 0% | 200.5 | 125,939 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 15 Aug 2022 | 628 | 31,174 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 1,667 | 9,400 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 188.22 per share. | 17 Jun 2022 | 722 | 8,678 (0%) | 0% | 188.2 | 135,898 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2022 | 392 | 7,906 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2022 | 392 | 392 | - | - | Restricted Stock Units - 1 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 185.57 per share. | 17 Jun 2022 | 173 | 7,733 (0%) | 0% | 185.6 | 32,104 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 5,203 | 31,802 | - | - | Non Qualified Stock Options | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 2,378 | 2,378 | - | - | Restricted Stock Units - 5 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 250.44 per share. | 20 Apr 2022 | 72 | 7,514 (0%) | 0% | 250.4 | 18,032 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 20 Apr 2022 | 72 | 26,559 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.85 per share. | 20 Apr 2022 | 72 | 7,586 (0%) | 0% | 51.8 | 3,733 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 23 Mar 2022 | 1,600 | 26,671 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.85 per share. | 23 Mar 2022 | 1,600 | 9,114 (0%) | 0% | 51.9 | 82,960 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 251.29 per share. | 23 Mar 2022 | 930 | 8,184 (0%) | 0% | 251.3 | 233,700 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 251.15 per share. | 23 Mar 2022 | 670 | 7,514 (0%) | 0% | 251.2 | 168,271 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 11 Nov 2021 | 1,000 | 30,029 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 317.12 per share. | 11 Nov 2021 | 1,000 | 7,514 (0%) | 0% | 317.1 | 317,120 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 97.78 per share. | 11 Nov 2021 | 1,000 | 8,514 (0%) | 0% | 97.8 | 97,780 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 309.86 per share. | 20 Oct 2021 | 2,000 | 7,514 (0%) | 0% | 309.9 | 619,720 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 20 Oct 2021 | 2,000 | 31,029 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 97.78 per share. | 20 Oct 2021 | 2,000 | 9,514 (0%) | 0% | 97.8 | 195,560 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 4,933 | 34,429 | - | - | Non Qualified Stock Options | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 1,537 | 1,537 | - | - | Restricted Stock Units - 3 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 1,303 | 1,303 | - | - | Restricted Stock Units - 4 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 89.70 per share. | 12 Aug 2021 | 1,000 | 8,514 (0%) | 0% | 89.7 | 89,700 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 12 Aug 2021 | 1,000 | 29,296 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 275.16 per share. | 12 Aug 2021 | 1,000 | 7,514 (0%) | 0% | 275.2 | 275,160 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 12 Jul 2021 | 1,000 | 30,496 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 89.70 per share. | 12 Jul 2021 | 1,000 | 8,514 (0%) | 0% | 89.7 | 89,700 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 278.77 per share. | 12 Jul 2021 | 1,000 | 7,514 (0%) | 0% | 278.8 | 278,770 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | 01 Jul 2021 | 1,000 | 31,496 | - | - | Non Qualified Stock Option | ||
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 267.04 per share. | 01 Jul 2021 | 1,000 | 7,514 (0%) | 0% | 267.0 | 267,040 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 89.70 per share. | 01 Jul 2021 | 1,000 | 8,514 (0%) | 0% | 89.7 | 89,700 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 4,676 | 9,633 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Sale of securities on an exchange or to another person at price $ 255.67 per share. | 15 Jun 2021 | 2,119 | 7,514 (0%) | 0% | 255.7 | 541,765 | Common Stock |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 681 | 0 | - | - | Restricted Stock Units - 2 | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 681 | 5,436 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | John V. Sakys | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 263.30 per share. | 15 Jun 2021 | 479 | 4,957 (0%) | 0% | 263.3 | 126,121 | Common Stock |